Assess whether the primary endpoint will survive FDA scrutiny (2df194)

SITUATION A live Pharma & Life Sciences CMC and Development Pathways file in an RWE group proposing a post-marketing study instead of a new RCT now turns on advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design. Clinical-development physician should state what that extract proves for whether the primary endpoint will survive FDA scrutiny.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after a pediatric ethicist objecting to the proposed design. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after a pediatric ethicist objecting to the proposed design for clinical-development physician. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after a pediatric ethicist objecting to the proposed design. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision the primary endpoint will turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a pediatric ethicist objecting to the proposed design and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design). If advisory-committee question list that exposes a weak secondary endpoint cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, clinical-development physician must state the unresolved clinical or safety evidence requirement explicitly.